johnson & johnson pharmaceutical research & development llc

Johnson & Johnson Pharmaceutical R&D Unveils Latest Breakthroughs

By
AD

Headquartered in New Brunswick, New Jersey, Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) is a division of Johnson & Johnson, one of the world's most renowned healthcare companies. This innovative entity is dedicated to the discovery, development, and delivery of novel pharmaceuticals that significantly improve the lives of patients globally. With a robust pipeline and a formidable legacy in healthcare, JJPRD is a leader in the pharmaceutical industry, driving advancements in key therapeutic areas, and setting new standards in patient care.

The primary focus of JJPRD is to develop transformative medicines across a broad range of disease states, including cancer, immunology, cardiovascular diseases, and infectious diseases. With a patient-centric approach, the company strives to understand the unique needs of patients, delivering tailored therapeutic solutions that address unmet medical needs and enhance the quality of life for those who rely on its therapies. This commitment to patients has resulted in a portfolio of over 130 products, with more than 65 promising candidates in clinical development.

Historical Milestones and Innovation

JJPRD's rich history is peppered with groundbreaking achievements that have forever changed the treatment landscape of various diseases. From introducing the first broad-spectrum antibiotic, Penicillin, to the market in 1944, to launching the first once-weekly formulation of a water-soluble bisphosphonate for the treatment of osteoporosis, JJPRD has consistently pushed the boundaries of pharmaceutical science, improving lives and redefining the future of healthcare.

AD
Johnson & Janssen Pharmaceutica NV Pharmaceutical Industry Biotech Research Development, LLC - Pharma PNG
Johnson & Janssen Pharmaceutica NV Pharmaceutical Industry Biotech Research Development, LLC - Pharma PNG
Johnson & Johnson raises dividend for 64th consecutive year as payout ratio holds near 59%
Johnson & Johnson raises dividend for 64th consecutive year as payout ratio holds near 59%
New Heart Drug From Novartis Gets FDA Approval -- Now The Major Pricing Battle Begins
New Heart Drug From Novartis Gets FDA Approval -- Now The Major Pricing Battle Begins

Its commitment to innovation is evident in the significant strides it has made in cancer treatment. JJPRD pioneered the development of Imbruvica, a targeted cancer therapy that has revolutionized the treatment of certain B-cell lymphomas and chronic lymphocytic leukemia. Additionally, its immuno-oncology portfolio, led by the blockbuster PD-1 inhibitor Darzalex, is advancing data-driven, personalized cancer care, demonstrating JJPRD's commitment to Targeted Immuno-oncology and delivering breakthrough therapies.

Immunology & Infectious Diseases

In the realm of immunology, JJPRD has made significant progress in understanding the intricacies of the human immune system. Its portfolio encompasses several blockbuster products catering to various autoimmune conditions. Stelara, for instance, a Phase 3-approved treatment for plaque psoriasis and moderate-to-severe Crohn's disease, reflects the company's commitment to improving outcomes and quality of life for patients with immunologic diseases. Furthermore, its robust pipeline includes several investigational therapies targeting autoimmune disorders, with the potential to revolutionize treatment paradigms.

Johnson & Johnson: Changing health for humanity
Johnson & Johnson: Changing health for humanity
Johnson & Johnson Building Plant in Pennsylvania
Johnson & Johnson Building Plant in Pennsylvania
U.S. judge rejects Johnson & Johnson's $10 billion baby powder settlement 10 Things, Johnson And Johnson Symbol
U.S. judge rejects Johnson & Johnson's $10 billion baby powder settlement 10 Things, Johnson And Johnson Symbol

In the fight against infectious diseases, JJPRD continues to develop new therapies that can tackle emerging threats. Its work in the prevention of HIV, including the development of the first once-daily, single-tablet regimen for people at high risk of acquiring HIV, demonstrates its steadfast commitment to global health and Disease Eradication Initiatives.

Cardiovascular & Metabolism

Cardiovascular disease remains one of the world's leading causes of death, an issue that JJPRD is actively addressing with innovative medicines. Its portfolio includes revolutionary therapies such as Praluent, an injectable treatment that significantly reduces the risk of cardiovascular events, and Invokana, a first-in-class SGLT2 inhibitor used to manage type 2 diabetes and reduce the risk of cardiovascular death.

AD

JJPRD's pipeline in this therapeutic area continues to evolve, with a focus on next-generation therapies that target unmet needs in cardiovascular disease and diabetes. Its research and development efforts in this space reflect the company's vision to transform the standard of care, improving patient outcomes and quality of life.

Johnson & Johnson Strengthens Pipeline with First-of-its-Kind Oral Psoriasis Drug | NewsCase
Johnson & Johnson Strengthens Pipeline with First-of-its-Kind Oral Psoriasis Drug | NewsCase
Johnson & Johnson e altre tre case farmaceutiche pagheranno 590 milioni di dollari ai nativi americani per la crisi da oppiacei che sta devastando le tribù
Johnson & Johnson e altre tre case farmaceutiche pagheranno 590 milioni di dollari ai nativi americani per la crisi da oppiacei che sta devastando le tribù
J&J To Invest $2B In North Carolina Biologics Project
J&J To Invest $2B In North Carolina Biologics Project
Johnson & Johnson Medical Devices Companies Announces Strategic Partnership with Microsoft to Further Enable its Digital Surgery Solutions
Johnson & Johnson Medical Devices Companies Announces Strategic Partnership with Microsoft to Further Enable its Digital Surgery Solutions
Johnson & Johnson requests emergency authorization from FDA for Covid vaccine
Johnson & Johnson requests emergency authorization from FDA for Covid vaccine
Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government - Johnson &
Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government - Johnson &

From its inception, JJPRD has been dedicated to translating scientific breakthroughs into transformative medicines. With a relentless pursuit of innovation, a strong legacy in the pharmaceutical industry, and a vision centered on patient needs, JJPRD continues to redefine the skyline of healthcare, delivering solutions that will shape the future of medicine. Staying true to its mission, through dedicated research, development, and perseverance, Johnson & Johnson Pharmaceutical Research & Development, LLC, continues to move us forward, setting new benchmarks in patient care and healing.

Johnson & Johnson cambia de logo después de 135 años
Johnson & Johnson cambia de logo después de 135 años
How Johnson & Johnson is supporting its global workforce during COVID-19
How Johnson & Johnson is supporting its global workforce during COVID-19
SCOTUS Declines Risperdal Appeal, J&J to Pay $124 M
SCOTUS Declines Risperdal Appeal, J&J to Pay $124 M
Evivo study on atopic dermatitis reduction
Evivo study on atopic dermatitis reduction
‘Bridge to Employment’ Program Preps Students to Study STEM, Health Sciences
‘Bridge to Employment’ Program Preps Students to Study STEM, Health Sciences
Johnson & Johnson in early talks to buy drugmaker Actelion
Johnson & Johnson in early talks to buy drugmaker Actelion
Johnson & Johnson Pays $1 Billion for Firefly Bio's KRAS-Targeting Platform
Johnson & Johnson Pays $1 Billion for Firefly Bio's KRAS-Targeting Platform
JOHNSON & JOHNSON
JOHNSON & JOHNSON
Johnson & Johnson Plans $1 Billion Cell Therapy Manufacturing Facility in Pennsylvania - Tradeline, Inc.
Johnson & Johnson Plans $1 Billion Cell Therapy Manufacturing Facility in Pennsylvania - Tradeline, Inc.
Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine
LinkedIn Case Study: How Johnson & Johnson Used LinkedIn To Promote Vaccine Take-Up [Infographic]
LinkedIn Case Study: How Johnson & Johnson Used LinkedIn To Promote Vaccine Take-Up [Infographic]
Johnson & Johnson hit with $572 million opioid ruling — what happens now?
Johnson & Johnson hit with $572 million opioid ruling — what happens now?
A Historic $41 Billion Spinoff from Johnson & Johnson
A Historic $41 Billion Spinoff from Johnson & Johnson
False claims, billion-dollar payouts, and silenced critics: the truth about Johnson & Johnson — Apple News In Conversation
False claims, billion-dollar payouts, and silenced critics: the truth about Johnson & Johnson — Apple News In Conversation
AD